RxDoctor Payments Data

Jordan Graybill, MD

Interventional Pain Medicine · Vancouver, WANPI 1053585802

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $941 of the $1,497 with a category attached, or 62.9%. 9 manufacturers reported payments, led by Si-bone, Inc. at 37.1% of the total. Reporting peaked in 2024 at $760 and has fallen 68.8% since, to $237 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in WA, where the typical reported total is $2,704.

$1,497in general payments, 2019–2025

Across 29 payments — averaging $51.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Si-bone, Inc.$556
  • Abbott$316
  • Boston Scientific$232
  • Pacira Pharmaceuticals Incorporated$203
  • Nevro Corp.$96
  • AbbVie$40
  • plus $55 from 3 others

What the payments were for

  • Travel & lodging$55637%
  • Food & beverage$94163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,497 in reported general payments places this provider in the 40th percentile of 30 interventional pain medicine providers in Washington.

See all interventional pain medicine providers in Washington

Medicare billing

Part B allowed, 2024
$140,499
Medicare patients
111
Services billed
9,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZubsolvBuprenorphine Hcl/Naloxone Hcl14$15,992
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl142$13,253
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen321$5,426
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen121$3,864
Gabapentin202$2,904
Oxycodone Hcl184$2,671
Lidocaine14$1,489
Topiramate81$1,335
Buprenorphine Hcl40$1,293
Hydromorphone Hcl51$1,275
Pregabalin96$1,019
Acetaminophen-CodeineAcetaminophen With Codeine31$898
Etodolac12$886
Baclofen109$786
Methocarbamol36$777

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →